European Journal of Cancer
Volume 37, Issue 4 , Pages 486-491 , March 2001

Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients

  • E Fernebro

      Affiliations

    • The Department of Oncology, The Jubileum Institution, University Hospital, S-221 85 Lund, Sweden
    • Corresponding Author InformationCorresponding author. Tel.: +46-46177500; fax: +46-46147327
    • ,
  • R.R Madsen

      Affiliations

    • The Finsen Laboratory, Copenhagen University Hospital, Copenhagen, Denmark
    • ,
  • M Fernö

      Affiliations

    • The Department of Oncology, The Jubileum Institution, University Hospital, S-221 85 Lund, Sweden
    • ,
  • N Brünner

      Affiliations

    • The Finsen Laboratory, Copenhagen University Hospital, Copenhagen, Denmark
    • ,
  • P.-O Bendahl

      Affiliations

    • The Department of Oncology, The Jubileum Institution, University Hospital, S-221 85 Lund, Sweden
    • ,
  • I.J Christensen

      Affiliations

    • The Finsen Laboratory, Copenhagen University Hospital, Copenhagen, Denmark
    • ,
  • A Johnson

      Affiliations

    • The Department of Oncology, Akademiska Hospital, Uppsala, Sweden
    • ,
  • M Nilbert

      Affiliations

    • The Department of Oncology, The Jubileum Institution, University Hospital, S-221 85 Lund, Sweden

Received 12 June 2000 ,Revised 16 October 2000 ,Accepted 22 November 2000.

References 

  1. McArdle CS, Hole D. Impact of variability among surgeons on postoperative morbidity and mortality and ultimate survival. Br. Med. J. 1991;302:1501–1505
  2. MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet. 1993;341:457–460
  3. Swedish Rectal Cancer Trial . Improved survival with preoperative radiotherapy in resectable rectal cancer. New Engl. J. Med. 1997;336:980–987
  4. Duffy MJ. Proteases as prognostic markers in cancer. Clin. Cancer Res. 1996;2:613–618
  5. Andreasen PA, Kjöller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis (a review). Int. J. Cancer. 1997;72:1–22
  6. Brünner N, Nielsen HJ, Hamers M, Christensen IJ, Thorlacius-Ussing O, Stephens RW. The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer. APMIS. 1999;107:160–167
  7. Duggan C, Maguire T, McDermott E, O'Higgins N, Fennelly JJ, Duffy MJ. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int. J. Cancer. 1995;61:597–600
  8. Gröndahl-Hansen J, Peters HA, van Putten WLJ, et al.  Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin. Cancer Res. 1995;1:1079–1087
  9. Ganesh S, Sier CF, Heerding MM, Griffionen G, Lamers CB, Verspaget HW. Urokinase receptor and colorectal cancer survival. Lancet. 1994;344:401–402
  10. Stephens RW, Pedersen AN, Nielsen HJ, et al.  ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin. Chem. 1997;43:1868–1876
  11. Sier CFM, Stephens R, Bizik J, et al.  The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res. 1998;58:1843–1849
  12. McCabe NP, Angwafo FF, Zaher A, Selman SH, Kouinche A, Jankun J. Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients. Oncol. Rep. 2000;4:879–882
  13. Stephens RW, Nielsen HJ, Christensen IJ, et al.  Plasma urokinase receptor levels in patients with colorectal cancer (relationship to prognosis). J. Natl. Cancer Inst. 1999;91:869–874
  14. American Joint Committee on Cancer . Cancer Staging Manual. 5th edn.. Philadelphia: Lippincott-Raven; 1998;
  15. StataCorp . Stata Statistical Software, release 6.0. College Station, TX: Stata Corporation; 1999;
  16. Pyke C, Kristensen P, Ralfkiaer E, et al.  Urokinas-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am. J. Pathol. 1991;138:1059–1067
  17. Holst-Hansen C, Hamers MJ, Johannessen BE, Brünner N, Stephens RW. Soluble urokinase receptor released from human carcinoma cells (a plasma parameter for xenograft tumor studies). Br. J. Cancer. 1999;81:203–211
  18. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J. 1996;15:1572–1582
  19. Höyer-Hansen G, Behrendt N, Ploug M, Danö K, Preissner KT. The intact urokinase receptor is required for efficient vitronectin binding (receptor cleavage prevents ligand interaction). FEBS Lett. 1997;420:79–85
  20. Wilhelm O, Weidle U, Höhl S, Rettenberger P, Schmitt M, Graeff H. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett. 1994;337:131–134

PII: S0959-8049(00)00422-6

European Journal of Cancer
Volume 37, Issue 4 , Pages 486-491 , March 2001

Article Tools

* Image Usage & Resolution